Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
GLP-1RAs: Mechanism of Action and Role in HFpEF Management
Author(s): Magdy Abdelhamid , Mostafa M Abdrabou , Emanuel Faris , et al Added: 7 months ago

Heart Failure
Understanding the Role of GLP-1 RAs in the Treatment of HF
Author(s): Giovanni Battista Bonfioli , Matteo Pagnesi , Daniela Tomasoni , et al Added: 9 months ago

Cardiovascular Kidney Metabolic

Heart Failure
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
GLP-1RA in Different HFpEF Phenotypes
Author(s): Aleksandra Bykova , Maria Serova , Maria Chashkina , et al Added: 1 year ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Apelin/APJ and Incretin Therapy in Heart Failure
Author(s): Dominic Marcel Alfonso Added: 3 months ago

MI/ACS

Heart Failure
The Role of GLP-1 in Heart Failure
Author(s): Amina Rakisheva , Anton Zatsarinnyy Added: 4 months ago

Inherited and Congenital Cardiac Conditions

Heart Failure
EASD 24: Effectiveness of Empagliflozin and GLP1s
Author(s): Phyo Htoo Added: 1 year ago
EASD 24 - Dr Phyo Htoo (Harvard Medical School, Boston, MA, US) joins us to discuss a study investigating the comparative effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists in combination as compared to either medication alone in patients with type 2 diabetes.Interview Questions:1. What was the reasoning for this study?2. What was the patient population and study design… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ESC HF 25: The PRAISE-HFrEF Study
Author(s): Varun Sundaram Added: 1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve… View more

Cardiovascular Kidney Metabolic

Heart Failure
Heart Failure in the Cardio-Renal-Metabolic Patient: Front-Line Decisions
Author(s): Debasish Banerjee Added: 4 days ago
Prof Debasish Banerjee (St George's University Hospitals NHS Foundation Trust, London, UK) joins us to discuss the practical management of heart failure in patients with coexisting chronic kidney disease (CKD) and diabetes, and how to close the gap between guideline recommendations and everyday clinical practice.In this interview, Prof Banerjee addresses one of the central challenges in cardio… View more

Cardiovascular Kidney Metabolic

Heart Failure
HFA 2026: Obesity and Natriuretic Peptides in Heart Failure — PORTHOS
Author(s): Rui Baptista Added: 2 weeks ago
HFA Congress 2026 — Dr Rui Baptista (University of Coimbra, Coimbra, PT) joins us to discuss findings from the PORTHOS (PORTuguese Heart Failure Observational Study), a nationwide, population-based epidemiological study examining heart failure prevalence and characteristics in mainland Portugal using contemporary diagnostic tools.PORTHOS enrolled 6,189 adults aged 50 and above, randomly selected… View more

Heart Failure